Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aducanumab PK comparability study (SC vs IV) in healthy volunteers
NCT05216887Phase 1Completed
- Sponsor
- Biogen
- Start
- Feb 2022
- Primary completion
- Jul 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of aducanumab in Alzheimer's disease (AD) (2 arms), sponsored by Biogen. Primary endpoint: Area Under the Concentration-Time Curve From Time 0 to Infinity at Day 99. Started Feb 2022; status: completed.
02
Drugs
aducanumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05216887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05216887.